GTSE1 Antibody

1. G2 and S-phase expressed 1 (GTSE1) expression promotes AM progression and correlates with clinical outcomes of patients with acral melanoma (AM), and may represent a promising therapeutic target to suppress AM progression. PMID: 29660787
2. GTSE1 is expressed exclusively in late G2 and M phase. From nuclear envelope breakdown until anaphase onset, GTSE1 binds preferentially to the most stable mitotic spindle microtubules and promotes their turnover. PMID: 28821562
3. Results indicated for the first time that overexpression of GTSE1 was involved in the progress of HCC, enhancing proliferation and promoting cell invasion in HCC cells. PMID: 27240802
4. Study identifies GTSE1 as a biomarker for cisplatin resistance in gastric cancer cells and suggests its repressive role in cisplatin induced apoptosis making it a potential therapeutic target for better clinical management of gastric cancer patients. PMID: 26209226
5. GTSE1 is a microtubule plus-end tracking protein that regulates EB1-dependent cell migration. PMID: 23236459
6. GTSE1 is overexpressed dramatically in lung cancer patients' tissues. PMID: 22292647
7. Data show that G2 and S-phase-expressed 1 (GTSE1) protein, a negative regulator of p53, is required for G2 checkpoint recovery and that Plk1 phosphorylation of GTSE1 promotes its nuclear localization. PMID: 20577264
8. hGTSE-1 mediated-p21(CIP1/WAF1) stabilization is clearly involved in the ability of cells to counteract cytotoxicity induced by the microtubule poison paclitaxel. PMID: 20018861
9. GTSE-1 controls DNA damage-induced apoptosis by affecting p53 function PMID: 12750368
10. requires an intact nuclear export signal and functional Mdm2 for the regulation of p53 PMID: 14707141

Show More

Hide All

HGNC: 13698

OMIM: 607477

KEGG: hsa:51512

STRING: 9606.ENSP00000415430

UniGene: Hs.386189